Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ORGANIZATION
ORGANIZATION
- Bayer Yakuhin President to Become New EFPIA Japan Chairman
October 2, 2014
- JPMA Weighs Disclosure of Ad Payments to Commercial Medical Publishers
September 26, 2014
- JPMA to Unify Method of Disclosing Sensitive Payment Information from Next Year
September 22, 2014
- JPMA to Suspend Hasegawa’s Veep Activities for Another 6 Months over CASE-J
September 19, 2014
- CDISC CEO Advises Drug Makers to Collect Data Based on CDASH
August 27, 2014
- NEDO, NCC, Toray to Jointly Develop Simple Test Systems for Cancers and Dementia
August 20, 2014
- Fair Discussions Necessary for Full Introduction of New Drug Development Premium: Chuikyo Member
August 12, 2014
- Drug Price Settlement Rate Will Rise towards Sept.: JPWA Chief
August 11, 2014
- OTC Drug Federation Requests Ministry to Advance Prescription-to-OTC Switches
July 31, 2014
- Generic Drugs See 45.1% Market Share in FY2013 in New Calculation
July 29, 2014
- JPMA President Hints at Adoption of Unified System to Disclose Fees Paid to Doctors Next Year
July 25, 2014
- Kampo Manufacturers Group Names Tsumura President as New Chairman
July 24, 2014
- Number of Drug Reps Rebounds to 65,752 in FY2013, Buoyed by Major Product Debuts
July 23, 2014
- Medwatcher Elbows Expert Group to Disclose Financial Links with HPV Vaccine Makers
July 22, 2014
- Generic Switch Saved 22.7 Billion Yen in Drug Costs over 5 Years: Kyokai Kenpo
July 17, 2014
- JGA to Use Independent Organizations to Conduct GMP Inspections of Overseas Drug Substance Production Facilities
July 17, 2014
- Cochrane Collaboration Establishes Japanese Branch; Co-Director Calls for “Full Disclosure” of Clinical Research
July 14, 2014
- Medwatcher Wants Structural Problems of Pharma Industry and Researchers Revealed During Diovan Trials
July 3, 2014
- JMA Exec Matsumoto Tipped to Replace Adachi as Chuikyo Rep
July 3, 2014
- “No Need to Step Down” as Chair of Biz Lobby, Govt Panel Member: Takeda CEO
July 2, 2014
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…